Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si-Meng Chen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|February 10, 2010
New microtubule-inhibiting anticancer agentsSi-Meng Chen, Ling-Hua Meng, Jian Ding
Molecular and Cellular Biochemistry|October 1, 2011
Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell lineJin-Jian Lu, Si-Meng Chen, Jian Ding, et al.
World Journal of Clinical Cases|February 13, 2020
Mesh repair of sacrococcygeal hernia <i>via</i> a combined laparoscopic and sacrococcygeal approach: A case reportYuan-Qiang Dong, Li-Jia Liu, Zan Fu, et al.
Investigational New Drugs|July 8, 2010
The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cellsJin-Jian Lu, Si-Meng Chen, Xiao-Wei Zhang, et al.
Biochemical Pharmacology|February 7, 2012
Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTORSi-meng Chen, Jia-li Liu, Xiang Wang, et al.
The Journal of Biological Chemistry|February 17, 2012
Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cellsGuang Chen, Si-Meng Chen, Xiang Wang, et al.
Acta Pharmacologica Sinica|January 19, 2018
The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8Jia-Jie Shi, Si-Meng Chen, Chen-Liang Guo, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2010
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutantTing Li, Jia Wang, Xiang Wang, et al.
Breast Cancer Research and Treatment|December 25, 2010
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivoJin-gui Ma, He Huang, Si-meng Chen, et al.
International Journal of Cancer|April 8, 2014
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancerSi-Meng Chen, Chen-Liang Guo, Jia-Jie Shi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|February 10, 2010
New microtubule-inhibiting anticancer agentsSi-Meng Chen, Ling-Hua Meng, Jian Ding
Molecular and Cellular Biochemistry|October 1, 2011
Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell lineJin-Jian Lu, Si-Meng Chen, Jian Ding, et al.
World Journal of Clinical Cases|February 13, 2020
Mesh repair of sacrococcygeal hernia <i>via</i> a combined laparoscopic and sacrococcygeal approach: A case reportYuan-Qiang Dong, Li-Jia Liu, Zan Fu, et al.
Investigational New Drugs|July 8, 2010
The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cellsJin-Jian Lu, Si-Meng Chen, Xiao-Wei Zhang, et al.
Biochemical Pharmacology|February 7, 2012
Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTORSi-meng Chen, Jia-li Liu, Xiang Wang, et al.
The Journal of Biological Chemistry|February 17, 2012
Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cellsGuang Chen, Si-Meng Chen, Xiang Wang, et al.
Acta Pharmacologica Sinica|January 19, 2018
The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8Jia-Jie Shi, Si-Meng Chen, Chen-Liang Guo, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2010
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutantTing Li, Jia Wang, Xiang Wang, et al.
Breast Cancer Research and Treatment|December 25, 2010
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivoJin-gui Ma, He Huang, Si-meng Chen, et al.
International Journal of Cancer|April 8, 2014
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancerSi-Meng Chen, Chen-Liang Guo, Jia-Jie Shi, et al.
Pageof 2